Literature DB >> 16105030

Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism.

Pierre D'Amour1, Jean-Hugues Brossard, Louise Rousseau, Loan Nguyen-Yamamoto, Edgard Nassif, Claude Lazure, Dany Gauthier, Jeffrey R Lavigne, Richard J Zahradnik.   

Abstract

BACKGROUND: Non-(1-84) parathyroid hormone (PTH) fragments are large circulating carboxyl-terminal (C) fragments with a partially preserved amino-terminal (N) structure. hPTH (7-84), a synthetic surrogate, has been demonstrated to exert biologic effects in vivo and in vitro which are opposite to those of hPTH (1-34) on the PTH/PTHrP type I receptor through a C-PTH receptor. We wanted to determine the N structure of non-(1-84) PTH fragments.
METHODS: Parathyroid cells isolated from glands obtained at surgery from three patients with primary hyperparathyroidism and three patients with secondary hyperparathyroidism were incubated with 35S-methionine to internally label their secretion products. Incubations were performed for 8 hours at the patient-ionized calcium concentration and in the presence of various protease inhibitors. The supernatant was fractionated by high-performance liquid chromatography (HPLC) and fractions were analyzed with PTH assays having (1 to 4) and (12 to 23) epitopes, respectively. The serum of each patient was similarly analyzed. Peaks of immunoreactivity identified were submitted to sequence analysis to recover the 35S-methionine residues in positions 8 and 18.
RESULTS: Three regions of interest were identified with PTH assays. They corresponded to non-(1-84) PTH fragments (further divided in regions 3 and 4), a peak of N-PTH migrating in front of hPTH (1-84) (region 2) and a peak of immunoreactivity corresponding to the elution position of hPTH (1-84) (region 1). The last corresponded to a single sequence starting at position 1. Region 2 gave similar results in all cases (a major signal starting at position 1) but also sometimes minor sequences starting at position 4 or 7. Regions 3 and 4 always identified a major sequence starting at positions 7 and minor sequences starting at positions 8, 10, and 15. Surprisingly, a major signal starting at position 1 was also present in region 3. The HPLC profile obtained from a given patient's parathyroid cells was qualitatively similar to the one obtained with his/her serum in each case.
CONCLUSION: These results indicate that non-(1-84) PTH fragments are composed of a family of fragments which may be generated by specific or progressive cleavage at the N region. The longest fragment starts at position 4 and the shortest at position 15. A peptide starting at position 7 appears as the major component of non-(1-84) PTH fragments. The generation process is similar to the one described for smaller C-PTH fragments a number of years ago, suggesting a similar production mechanism and source for all C-PTH fragments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105030     DOI: 10.1111/j.1523-1755.2005.00493.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

Review 1.  Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.

Authors:  J C Souberbielle; P Boudou; C Cormier
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

2.  LC-MS/MS in the Clinical Laboratory - Where to From Here?

Authors:  Stefan Kg Grebe; Ravinder J Singh
Journal:  Clin Biochem Rev       Date:  2011-02

3.  Combining early postoperative parathyroid hormone and serum calcium levels allows for an efficacious selective post-thyroidectomy supplementation treatment.

Authors:  Marco Raffaelli; Carmela De Crea; Cinzia Carrozza; Gerardo D'Amato; Cecilia Zuppi; Rocco Bellantone; Celestino P Lombardi
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 4.  Normocalcemic primary hyperparathyroidism.

Authors:  John P Bilezikian; Shonni J Silverberg
Journal:  Arq Bras Endocrinol Metabol       Date:  2010-03

5.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-jing Wang; Robert Elashoff; Barbara Gales; Mara J Horwitz; Andrew F Stewart; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

Review 6.  International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors.

Authors:  Thomas J Gardella; Jean-Pierre Vilardaga
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 8.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

9.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

10.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-Jing Wang; Shobha Sahney; Barbara Gales; Robert M Elashoff; Harald Jüppner; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2009-03-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.